GET THE APP

..

Journal of Integrative Oncology

ISSN: 2329-6771

Open Access

Volume 7, Issue 2 (2018)

Research Article Pages: 1 - 4

Combined Effects of Ethylacetate Extracts of Propolis Inducing Cell Death of Human Colorectal Adenocarcinoma Cells

Britta Schulz, Elizabeth Smith, Richard Funden and Ulf Moosberger

DOI: 10.4172/2329-6771.1000207

Since antiquity, propolis has been said to show anti-cancerous effects in the treatment of human breast cancer cells or human colorectal carcinoma cells, all in connection with alterations in the apoptosis pathways. At the same time, therapeutics like D, L-methadone have shown success in amendments of such pathways, being associated with changes in cancer cell morphology and at the same time, serving as a beneficial analgesic during chemotherapy. Using ethylacetate extracts of wax-free Bio99T M propolis tincture, which is exclusively distributed by our commercial partners, we showed a combination of those effects in an, both of apoptotic and analgesic nature, with a success outcompeting prevailing chemotherapeutic procedures in the treatment of human colorectal adenocarcinoma cells. We therefore suggest a reconsideration of the prevail of common cancer treatments and instead, focusing on the research on natural alternatives in the form of propolis extracts.
Research Article Pages: 1 - 3

Pilot Screening Study of the Angiogenesis Factor Pleiotrophin (PTN) in Serum Samples from Patients of Various Disease Groups

Gerhard Zugmaier, Athanasios Karalis, Cornelius Knabbe and Achim Aigner

DOI: 10.4172/2329-6771.1000208

Introduction: The secreted growth factor pleiotrophin (PTN) belongs to the midkine family of heparin-binding growth factors and is tightly regulated during embryogenesis. In contrast to its very limited expression in normal adult tissues, PTN protein levels are markedly increased in different tumors, with PTN showing mitogenic, chemotactic, transforming, pro-angiogenic, pro-invasive and pro-metastatic activity. However, little is known about PTN upregulation in diseases other than cancer. The aim of this study was to investigate PTN serum levels in patients with various non-malignant chronic or acute disorders, and in pregant women, compared to healthy nonpregnant blood donors as negative control group.
Materials and Methods: PTN serum levels were determined by a sandwich ELISA.
Results: PTN serum levels were found to be significantly elevated with a p-value of <0.05 in patients with the acute non-malignant disorders, acute inflammation, acute vascular disease and acute trauma. In patients with chronic leukemia and solid tumors, and pregnancy, increased PTN serum levels were detected as well.
Conclusion: Beyond its described functions in solid tumors and in the central nervous system, these data indicate that PTN is an acute phase protein in the adult organism and that, due to its upregulation under various non-cancer conditions, special caution must be taken when exploring PTN serum levels as potential tumor marker.

arrow_upward arrow_upward